CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
The occurrence and frequency of anaphylactic reactions in the use of infliximab – a prospective study in a large single center
DOI 10.1055/s-0028-1096440
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Jürgens, C Tillack, J Seiderer, S Pfennig, B Göke, S Brand, T Ochsenkühn
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe10/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Antagonizing Tumor Necrosis Factor Alpha (TNFα) has become an effective strategy in treatment of moderate and severe Crohn's disease (CD) and ulcerative colitis (UC). Infliximab (Remicade, Schering Plough), a recombinant IgG1 monoclonal antibody, was the first TNF-α-antibody approved for the treatment of CD and UC, respectively. Since anaphylactic reactions occur frequently with infliximab, we analyzed…
Zitieren
Zitierempfehlung
M Jürgens, C Tillack, J Seiderer, S Pfennig, B Göke, S Brand, T Ochsenkühn (2008) The occurrence and frequency of anaphylactic reactions in the use of infliximab – a prospective study in a large single center. Zeitschrift für Gastroenterologie (10). https://doi.org/10.1055/s-0028-1096440
Mit CareLit weiterarbeiten